Data Creation, Analysis and Extraction Technologies and the Advancement of Research and Development
First written in FY2016. 3 of 36 entries say "Advanced", first in FY2021. Latest entry: FY2026.
90 other companies' latest entry also says "Other".
- FY2026Annual update of R&D spending and headcountAnnual report
「The total amount of the Group's research and development activities during the current consolidated fiscal year was ¥771 million. The Group focused on developing functions to generate revenue in its healthcare business, as well as improving the efficiency and enhancing the functionality of existing systems providing services, and recorded ¥663 million as software and ¥59 million as software under development.」
The company stated that it recorded ¥771 million in total research and development activities, including ¥663 million in software and ¥59 million in software under development, with a focus on functional development and improving the efficiency and enhancing the functionality of existing systems. Research and development staff totaled 59, or 16.2% of total employees. - FY2026-H1Update to interim research and development activity expensesAnnual report
「The amount of the Group's research and development activities during the current interim consolidated accounting period was ¥426 million. Depending on their content, the results of the Group's research and development activities are recorded as either software or research and development expenses.」
The company disclosed research and development activity expenses of ¥426 million for the interim consolidated accounting period. - FY2025Update to research and development activity expenses and staffingAnnual report
「The total amount of the Group's research and development activities during the current consolidated fiscal year was ¥606 million. The Group focused on developing functions to generate revenue in its healthcare business, as well as improving the efficiency and enhancing the functionality of existing systems providing services, and recorded ¥568 million as software and software under development.」
The company disclosed total research and development activities of ¥606 million, including ¥568 million recorded as software and related items, and 50 research and development staff members, representing 13.6% of total employees. - FY2025-H1Disclosure of interim research and development activity expensesAnnual report
「The amount of the Group's research and development activities during the current interim consolidated accounting period was ¥427 million. Depending on their content, the results of the Group's research and development activities are recorded as either software or research and development expenses.」
The company disclosed research and development activity expenses of ¥427 million for the interim consolidated accounting period and recorded the results as either software or research and development expenses. - FY2024AdvancedAnnual report
「The total amount of the Group's research and development activities during the current consolidated fiscal year was ¥794 million. The Group focused on developing functions to generate revenue in its healthcare business, as well as improving the efficiency and enhancing the functionality of existing systems providing services, and recorded ¥473 million as software and ¥259 million as software under development. The Group also developed new services and improved existing services, resulting in research and development expenses of ¥62 million. The Group had 48 research and development staff members, representing 12.8% of total employees.」
The company disclosed total research and development activities of ¥794 million, including ¥473 million in software and ¥259 million in software under development, focused on functional development and strengthening existing systems, and 48 research and development staff members. - FY2024-Q3Disclosure of cumulative third-quarter R&D spendingAnnual report
「The amount of the Group's research and development activities during the third quarter of the current consolidated cumulative period was ¥555 million. Depending on their content, the results of the Group's research and development activities are recorded as either software or research and development expenses. There were no material changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company disclosed research and development activity expenses of ¥555 million for the third-quarter cumulative period and stated that there were no material changes in the status of its research and development activities. - FY2024-Q2Disclosure of cumulative second-quarter R&D spendingAnnual report
「The amount of the Group's research and development activities during the second quarter of the current consolidated cumulative period was ¥374 million. Depending on their content, the results of the Group's research and development activities are recorded as either software or research and development expenses. There were no material changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
The company disclosed research and development activity expenses of ¥374 million for the second-quarter cumulative period and stated that there were no material changes in the status of its research and development activities. - FY2024-Q1Disclosure of first-quarter R&D spendingAnnual report
「The amount of the Group's research and development activities during the first quarter of the current consolidated cumulative period was ¥195 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company disclosed research and development activity expenses of ¥195 million for the first-quarter cumulative period, while stating that there were no material changes in the status of its research and development activities. - FY2023-Q3Disclosure of cumulative third-quarter R&D spendingAnnual report
「The amount of the Group's research and development activities during the third quarter of the current consolidated cumulative period was ¥554 million. There were no material changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company disclosed research and development activity expenses of ¥554 million for the third-quarter cumulative period, while stating that there were no material changes in the content of its research and development activities. - FY2023-Q2Disclosure of cumulative second-quarter R&D spendingAnnual report
「The amount of the Group's research and development activities during the second quarter of the current consolidated cumulative period was ¥345 million.」
The company disclosed research and development activity expenses of ¥345 million for the second-quarter cumulative period and stated that there were no material changes in the status of its research and development activities. - FY2023-Q1Disclosure of first-quarter R&D spendingAnnual report
「The amount of the Group's research and development activities during the first quarter of the current consolidated cumulative period was ¥111 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company disclosed research and development activity expenses of ¥111 million for the first-quarter cumulative period, while stating that there were no material changes in the status of its research and development activities. - FY2022AdvancedAnnual report
「During the fiscal year, R&D covered the development of new services, enhancements to the existing data health operations system, improvements to the polypharmacy support system, and efficiency improvements and functional enhancements to the company's own systems used to provide other medical information services. The Group had 19 R&D staff, representing 8.3% of total employees.」
The company carried out R&D on new services, the data health operations system and the polypharmacy support system, among others, and disclosed 19 R&D staff, total R&D activity spending of ¥441 million and R&D expenses of ¥223 million. - FY2022-Q3Disclosure of cumulative third-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative third quarter was ¥326 million.」
It disclosed cumulative third-quarter R&D activity spending of ¥326 million, while stating that there were no material changes in the status of R&D activities. - FY2022-Q2Disclosure of cumulative second-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative second quarter was ¥209 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
While stating that there were no material changes in the content of R&D activities, it disclosed cumulative second-quarter R&D activity spending of ¥209 million. - FY2022-Q1Disclosure of first-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative first quarter was ¥96 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
It disclosed cumulative first-quarter R&D activity spending of ¥96 million and stated that there were no material changes in the status of R&D activities. - FY2021AdvancedAnnual report
「During the fiscal year, R&D covered the development of new services, enhancements to the existing data health operations system, improvements to the polypharmacy support system, and efficiency improvements and functional enhancements to the company's own systems used to provide other medical information services.」
The company developed new services, enhanced the data health operations system and improved the polypharmacy support system, and disclosed total R&D activity spending of ¥287 million and R&D expenses of ¥141 million. - FY2021-Q3Disclosure of cumulative third-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative third quarter was ¥198 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
While stating that there were no material changes in the content of R&D activities, it disclosed cumulative third-quarter R&D activity spending of ¥198 million. - FY2021-Q2Disclosure of cumulative second-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative second quarter was ¥141 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative second-quarter R&D activity spending of ¥141 million. - FY2021-Q1Disclosure of first-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative first quarter was ¥65 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative first-quarter R&D activity spending of ¥65 million. - FY2020Update on R&D activities and scaleAnnual report
「During the fiscal year, R&D covered enhancements to the support system for addressing polypharmacy, the health program support system and the data health operations system, as well as efficiency improvements and functional enhancements to the company's own systems used to provide other medical information services.」
There were 24 R&D staff and total R&D activity spending of ¥124 million, and the company carried out enhancements to the support system for addressing polypharmacy and other systems. It also newly disclosed patented technology related to the provision of medication information. - FY2020-Q3Disclosure of cumulative third-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative third quarter was ¥76 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
While stating that there were no material changes in the status of R&D activities, it disclosed cumulative third-quarter R&D activity spending of ¥76 million. - FY2020-Q2Disclosure of cumulative second-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative second quarter was ¥59 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative second-quarter R&D activity spending of ¥59 million. - FY2019Update on R&D activities and scaleAnnual report
「During the fiscal year, R&D covered enhancements to the support system for addressing polypharmacy, the health program support system and the data health operations system, as well as efficiency improvements and functional enhancements to the company's own systems used to provide other medical information services.」
It identifies enhancements to the support system for addressing polypharmacy and other systems as R&D targets. There were 22 R&D staff, total R&D activity spending was ¥151 million, and R&D expenses were ¥103 million. - FY2019-Q3Disclosure of cumulative third-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative third quarter was ¥108 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative third-quarter R&D activity spending of ¥108 million. - FY2019-Q2Disclosure of cumulative second-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative second quarter was ¥78 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative second-quarter R&D activity spending of ¥78 million. - FY2019-Q1Disclosure of first-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative first quarter was ¥35 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative first-quarter R&D spending of ¥35 million. - FY2018Update on R&D activities and scaleAnnual report
「During the fiscal year, R&D covered the new development of a support system for addressing polypharmacy, enhancements to the health program support system, the data health operations system and the claims review system, as well as efficiency improvements and functional enhancements to the company's own systems used to provide other medical information services.」
It added new development of a support system for addressing polypharmacy and disclosed 23 R&D staff, total R&D activity spending of ¥171 million and R&D expenses of ¥134 million. - FY2018-Q3Disclosure of cumulative third-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative third quarter was ¥124 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative third-quarter R&D spending of ¥124 million. - FY2018-Q2Disclosure of cumulative second-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative second quarter was ¥77 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative second-quarter R&D spending of ¥77 million. - FY2018-Q1Disclosure of first-quarter R&D spendingAnnual report
「The Group's R&D activity spending for the cumulative first quarter was ¥40 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative first-quarter R&D spending of ¥40 million. - FY2017Update on R&D activities and scaleAnnual report
「During the fiscal year, R&D covered systems development related to polypharmacy notifications, enhancements to the health program support system, the data health operations system and the claims review system, as well as efficiency improvements and functional enhancements to the company's own systems used to provide medical information services. The Group had 22 R&D staff, representing 12.0% of total employees.」
It added polypharmacy notifications to the R&D scope and disclosed 22 R&D staff across the Group, representing 12.0% of total employees, and total R&D activity spending of ¥161 million. - FY2017-Q3Disclosure of cumulative third-quarter R&D spendingAnnual report
「The company's R&D activity spending for the cumulative third quarter was ¥122 million. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative third-quarter R&D spending of ¥122 million. - FY2017-Q2Disclosure of cumulative R&D spendingAnnual report
「The company's R&D activity spending for the cumulative second quarter was ¥79 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
While stating that there were no material changes in R&D activities, it disclosed cumulative second-quarter R&D spending of ¥79 million. - FY2017-Q1Disclosure of quarterly R&D spendingAnnual report
「The company's R&D activity spending for the cumulative first quarter was ¥44 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」
While stating that there were no material changes in R&D activities, it disclosed R&D spending of ¥44 million for the first quarter. - FY2016Update on R&D activities and scaleAnnual report
「During the fiscal year, R&D covered enhancements to the functions of the health program support system, the data health operations system and the claims review system, as well as efficiency improvements and functional enhancements to the company's own systems used to provide medical information services. The company had 18 R&D staff, representing 16.1% of total employees.」
It identifies multiple services and in-house systems as R&D targets and reports 18 staff, representing 16.1% of total employees. - FY2016First statedAnnual report
「Going forward, the company will conduct R&D to further improve the analytical capabilities required for each service, as well as research and experiments jointly with universities and other research institutions to statistically validate its analyses.」
It identifies improving analytical capabilities and joint research and experiments with universities and other institutions as specific initiatives. It states that the company had 17 R&D staff and total R&D activity spending of ¥125 million during the fiscal year.